Viatris Reports Third-Quarter Revenue of $3.75B, EPS Loss of $0.28
Revenue was essentially flat year over year as Viatris’ net loss widened. Stronger sales in Greater China and North America, including new products and estradiol transdermal products, were offset by base-business erosion from supply constraints and competition.
Viatris’ third-quarter revenue was essentially flat year over year, while its net loss widened. Stronger sales in Greater China and North America, including new products and estradiol transdermal products, were offset by base-business erosion from supply constraints and competition; a higher tax pr…